BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17878803)

  • 21. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
    J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization.
    Begnami MD; Palau M; Rushing EJ; Santi M; Quezado M
    Hum Pathol; 2007 Sep; 38(9):1345-50. PubMed ID: 17509660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas.
    Hamada Y; Iwaki T; Fukui M; Tateishi J
    Surg Neurol; 1997 Oct; 48(4):395-400. PubMed ID: 9315139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
    Welling DB
    Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
    Hagel C; Stemmer-Rachamimov AO; Bornemann A; Schuhmann M; Nagel C; Huson S; Evans DG; Plotkin S; Matthies C; Kluwe L; Mautner VF
    Neuropathology; 2012 Dec; 32(6):611-6. PubMed ID: 22394059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A group of schwannomas with interstitial deletions on 22q located outside the NF2 locus shows no detectable mutations in the NF2 gene.
    Bruder CE; Ichimura K; Tingby O; Hirakawa K; Komatsuzaki A; Tamura A; Yuasa Y; Collins VP; Dumanski JP
    Hum Genet; 1999 May; 104(5):418-24. PubMed ID: 10394935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
    Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
    Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
    Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
    Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
    Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
    Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
    Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
    Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
    Ruggieri M; Iannetti P; Polizzi A; La Mantia I; Spalice A; Giliberto O; Platania N; Gabriele AL; Albanese V; Pavone L
    Neuropediatrics; 2005 Feb; 36(1):21-34. PubMed ID: 15776319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of neurofibromatosis-associated tumours.
    Lin AL; Gutmann DH
    Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple cutaneous plexiform schwannomas as initial presentation of neurofibromatosis 2 in a 9-year-old.
    Nguyen TV; Matthews MR; Barrera FF; Browning JC
    Pediatr Dermatol; 2012; 29(4):536-8. PubMed ID: 21906157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
    Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
    J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.
    Evans DG; Lye R; Neary W; Black G; Strachan T; Wallace A; Ramsden RT
    J Neurol Neurosurg Psychiatry; 1999 Jun; 66(6):764-7. PubMed ID: 10329751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoblotting analysis of schwannomin/merlin in human schwannomas.
    Harwalkar JA; Lee JH; Hughes G; Kinney SE; Golubić M
    Am J Otol; 1998 Sep; 19(5):654-9. PubMed ID: 9752976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
    Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
    Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor.
    MacCollin M
    Brain Dev; 1995; 17(4):231-8. PubMed ID: 7503383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.